Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03259633
Title An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
Recruitment Approved for marketing
Gender both
Phase Expanded access
Variant Requirements No
Sponsors AstraZeneca
Indications

neurofibroma

Therapies

Selumetinib

Age Groups: adult | child | senior
Covered Countries USA


No variant requirements are available.